Medical technology company GE HealthCare (NASDAQ: GEHC) announced on Wednesday that it has introduced a new AI-enabled application orchestration feature, integrated into its True PACS and Centricity PACS systems, through a collaboration with Blackford.
This new offering aims to assist radiologists in managing increased workloads and exam complexities, enabling quicker diagnoses and treatments. The platform provides access to a catalog of third-party AI applications, covering areas from mammography to lung scans.
As clinician burnout rises - 49% of radiologists cited excessive bureaucratic tasks as a key issue in an RSNA survey - GE HealthCare's AI solutions focus on improving workflow efficiency. This aligns with the company's precision care framework, which integrates smart devices, targeted therapies, and digital solutions to enhance care quality.
GE HealthCare currently leads the U.S. Food and Drug Administration's (FDA) list of AI-enabled medical devices, with 80 clearances to date. The AI orchestration feature simplifies the integration of AI into clinical workflows, offering a streamlined process for healthcare providers to access and implement imaging AI solutions.
The new technology will be showcased at the Radiological Society of North America's annual meeting in Chicago from 1-4 December 2023.
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial